HackensackUMC Mountainside Cancer Center Chosen as Research Site For National Breast Cancer Study
April 21, 2016 12:22 PM
The National Institutes of Health has awarded a $2 million grant to Menssana Research to evaluate a rapid point-of-care breath test for breast cancer.HackensackUMC Mountainside has been named one of the five medical centers participating in the study, which include University of Southern California in Los Angeles, University of Texas MD Anderson Medical center in Houston, Seattle Swedish Medical Center, and Saint Michael’s Newark.
The BreathLink test analyzes breath for chemical biomarkers of breast cancer in six minutes. 2,000 women at risk of breast cancer will have their breath analyzed with BreathLink to determine if breath testing combined with a mammogram is more accurate than a mammogram alone.
Breast imaging with film and digital mammography are the standard tools for breast cancer screening but a false-positive test result can lead to over-diagnosis and further testing with repeat mammograms and breast biopsy. Researchers will determine if an added BreathLink breath test can help reduce the risk of a false-positive mammogram result, and so reduce the amount of needless follow-up testing.
Dr. Michael Phillips, developer of the BreathLink test and CEO of Menssana Research, Inc. said: “There’s a lot of room for improvement in breast cancer screening. Many women find mammograms uncomfortable and they are concerned about radiation exposure. That’s why our research team at Menssana has worked hard for years to develop a breath test for breast cancer. We’ve also found breath biomarkers for other diseases such as lung cancer, pulmonary tuberculosis and influenza. Breath tests offer great advantages - they are painless, safe, and inexpensive. If given the choice, most people would prefer a breath test to being stuck with a needle. In coming years, physicians and patients may think of a breath test as a convenient way to screen for several diseases while they are still in their earliest and most treatable stages.”
HackensackUMC Mountainside offers a range of oncology services and access to promising clinical trials, all in a program that puts leading research into action. Since 2012, Dr. Jan Huston has served as Medical Director of the Breast Center at HackensackUMC Mountainside.
“We are honored to be chosen to participate in this important trail,” said Dr. Huston. “HackensackUMC Mountainside's recently enhanced and expanded Breast Health Program provides the finest quality care, the latest technology and research that provide every patient personalized attention and support. We are able to do this because we've assembled an award-winning, multidisciplinary practice – a team-oriented approach involving surgeons, radiologists, medical oncologists, radiation oncologists, genetic counselors, social workers and others.”
The HackensackUMC Mountainside Cancer Center is accredited with commendation by the American College of Surgeons' Commission on Cancer, a designation awarded to only about one-fourth of all hospitals that provide cancer care nationwide.
About HackensackUMC Mountainside
HackensackUMC Mountainside has been serving Montclair and its surrounding New Jersey communities since 1891. The hospital, part of the Hackensack University Health Network, provides patients immediate access to innovative and effective treatment alternatives at specialized centers within the hospital that focus on imaging, women’s health, cancer care, surgery, obesity, stroke and chronic kidney disease. HackensackUMC Mountainside is designated as a Primary Stroke Center by the NJ State Department of Health and Senior Services and is one of only a few community hospitals licensed by the State to perform emergency cardiac angioplasty. To learn more about HackensackUMC Mountainside visit www.mountainsidehosp.com.